Accès ouvert
2023
article
OpenAlex
Megan Yerton, Allison Winter, Dario Gelevski, Grace Addy et autres
INTRODUCTION/AIMS: Expanded access protocols (EAPs) are a Food and Drug Administration (FDA)-regulated pathway for granting access to investigational products (IPs) to individuals with serious diseases who are ineligible for clinical trials. There is limited information about the use of EAPs in amyotrophic …
us
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Dario Gelevski, Grace Addy, Margot Rohrer, Caroline Cohen et autres
INTRODUCTION/AIMS: IC14 (atibuclimab) is a monoclonal anti-CD14 antibody. A previous phase 1 trial of 10 participants with amyotrophic lateral sclerosis (ALS) demonstrated initial safety of IC14 in an acute treatment setting. We provided long-term treatment with IC14 to individuals with ALS via …
us
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Megan Yerton, Allison Winter, Anthony Kostov, Cassandra Lieberman et autres
INTRODUCTION/AIMS: Lipid peroxidation is thought to play a biologically important role in motor neuron death in amyotrophic lateral sclerosis (ALS). 11,11 Di-deuterated linoleic ethyl ester (RT001) prevents lipid peroxidation in cellular and mitochondrial membranes. Herein we report on the use of RT001 …
us
(code pays fourni par la source)